Ocumetics Technology Corp (OTC:OTCFF) Financings

Ocumetics Technology Corp

Financings

RaiseDateIn US dollars
Private placement of units
Closed: C$3.11M raised · C$0.4 a unit · 1 warrant at C$0.5 for 36 months · Ventum Financial Corp. +1
Dealers: Ventum Financial Corp. (finder), Canaccord Genuity Corp. (finder)
Use of proceeds: First-in-human clinical trials, ongoing research and development and general working capital
Aug 24, 2026
Not stated
Update: raise
Use of proceeds: Fund completion of the first-in-human clinical study and support manufacturing, regulatory and commercialization activities
Jul 9, 2026
Private placement of units
Announced: up to C$1.54M · C$0.55 a unit · 1 warrant at C$0.75 for 36 months
Use of proceeds: First in-human clinical trials, ongoing research and development, and general working capital
Apr 29, 2026US$1.13M
Private placement of units
Closed: C$1.02M raised · C$0.6 a unit · 1 warrant at C$0.75 for 36 months · Centurion One Capital Corp.
Dealers: Centurion One Capital Corp. (lead)
Buyers: Dean Burns; Roger Jewett; Garth Webb; Doyle Stulting; J. Barton McRoberts; Michael Edwards
Insiders: Directors Dean Burns (CEO), Roger Jewett (CFO), Garth Webb, Doyle Stulting, J. Barton McRoberts and Michael Edwards participated; related party transaction under MI 61-101
Use of proceeds: First-in-human clinical trials, ongoing research and development and general corporate purposes
Feb 10, 2026
Private placement of units
Tranche closed: C$235,450 raised · C$0.6 a unit · Warrants at C$0.75 · Centurion One Capital Corp.
Dealers: Centurion One Capital Corp.
Jan 2, 2026US$171,398
Private placement of units
Closed: C$1.12M raised · C$0.35 a unit · ½ warrant at C$0.5 for 24 months · Numus Capital Corp.
Dealers: Numus Capital Corp.
Buyers: Michael Edwards
Insiders: Michael Edwards, a director of the Corporation, participated in the Private Placement.
Use of proceeds: Ongoing research and development
Aug 12, 2025

Read by 6ix AI from the company's releases